Tenacia Biotechnology

Tenacia Biotechnology is a commercial-stage biopharmaceutical company founded in 2022 by Bain Capital and headquartered in Shanghai, China. The company is dedicated to developing innovative therapeutics for patients with underserved neurological disorders, with a focus on central nervous system (CNS) diseases. Led by CEO Dr. Xiaoxiang Chen, a 25-year veteran of multinational biopharmaceutical organizations including Wyeth and Boehringer Ingelheim, Tenacia has assembled a seasoned management team with deep expertise in translational medicine, clinical development, and regulatory affairs. The company builds its pipeline around clinically de-risked neuroscience assets and pursues both internal R&D and strategic partnerships, including a $308M deal with Rapport Therapeutics for the epilepsy drug RAP-219 and a collaboration with Insilico Medicine on AI-driven CNS drug discovery. Tenacia operates at the intersection of global neuroscience innovation and the large unmet clinical need in the China market, with ambitions to become a leading CNS company in China.